Lamivudine (LAM) — Competitive Intelligence Brief

Lamivudine (LAM) (Lamivudine (LAM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus reverse transcriptase Infectious Disease Small molecule

Target snapshot

Lamivudine (LAM) (Lamivudine (LAM)) — Hoffmann-La Roche. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting the reverse transcriptase enzyme.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lamivudine (LAM) TARGET	Lamivudine (LAM)	Hoffmann-La Roche	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; Hepatitis B virus reverse transcriptase
3TC	3TC	Avexa	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; hepatitis B polymerase
Lamivudine/Zidovudine	Lamivudine/Zidovudine	Bristol-Myers Squibb	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Truvada Pill	Truvada Pill	University of North Carolina, Chapel Hill	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Once-daily ABC+3TC	Once-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Telbivudine treatment	Telbivudine treatment	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class